Abstract
Fulminant type 1 diabetes is a recently discovered subtype of type 1 diabetes. It is defined as diabetes in which the process of β-cell destruction and the progression of hyperglycemia and ketoacidosis are extremely rapid. The pathogenesis of this disease remains to be clarified, but the involvement of both genetic background—especially human leukocyte antigen genes—and viruses has been suggested. Fulminant type 1 diabetes has the following clinical characteristics: duration of hyperglycemic symptoms is 4 days on average; there is a high prevalence of preceding common-cold-like and gastrointestinal symptoms; there is a near-normal level of glycated hemoglobin in spite of very high plasma glucose levels associated with ketoacidosis; the disease is sometimes related to pregnancy; and there are increased serum pancreatic enzyme levels, absent C-peptide levels, but virtually no detectable autoantibodies against constituents of pancreatic β cells. The presence of the above characteristics strongly indicates the diagnosis of fulminant type 1 diabetes. Once the diagnosis of this disease is suspected, treatment of diabetic ketoacidosis must be started immediately, as in all other cases of type 1 diabetes. Otherwise, the death of the patient is likely to occur within 24 h. All medical practitioners must remember that this extremely rapidly progressing type of diabetes does exist, and they must pay special attention not to overlook it.
Key Points
-
Fulminant type 1 diabetes is defined as diabetes in which the progression from normoglycemia to hyperglycemia accompanied with ketoacidosis is extremely rapid
-
Without appropriate therapy, the death of the patient is inevitable within several days
-
Clinical features include common-cold-like and/or abdominal symptoms preceding disease onset, disease duration of less than 1 week from the start of hyperglycemia, a near-normal glycated hemoglobin level, no residual insulin secretory capacity, a lack of anti-islet autoantibodies, and elevation of pancreatic enzyme levels; association with pregnancy is not rare
-
Human leukocyte antigen DR4–DQ4 confers susceptibility to the disease, and viruses are suspected to be involved in the pathogenesis
-
Fulminant type 1 diabetes at onset should be treated the same as other diabetic ketoacidosis with intravenous infusion of saline and regular insulin; this treatment should be followed by an intensive insulin therapy including continuous subcutaneous insulin infusion
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Diabetes Association (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183–1197
Alberti KG and Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15: 539–553
Imagawa A et al. (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342: 301–307
Imagawa A et al. (2000) A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence. Ann Med 32: 539–543
Imagawa A et al. (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26: 2345–2352
Murao S et al. (2004) Differences in the contribution of HLA-DR and -DQ haplotypes to susceptibility to adult-onset and childhood-onset type 1 diabetes in Japanese patients. Diabetes 53: 2684–2690
Urakami T et al. (2002) A subtype of markedly abrupt onset with absolute insulin deficiency in idiopathic type 1 diabetes in Japanese children. Diabetes Care 25: 2353–2354
Pozzilli P et al. (2000) No evidence of rapid onset (Japanese) Type I diabetes in Caucasian patients. Diabetologia 43: 1332
Weets I et al. (2002) Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. J Clin Endocrinol Metab 87: 2597–2605
Maldonado M et al. (2003) Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and β-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab 88: 5090–5098
Balasubramanian K et al. (2003) High frequency of type 1B (idiopathic) diabetes in north Indian children with recent-onset diabetes. Diabetes Care 26: 2697
Vreugdenhil GR et al. (2000) Acute onset of type I diabetes mellitus after severe echovirus 9 infection: putative pathogenic pathways. Clin Infect Dis 31: 1025–1031
Jung TS et al. (2004) A Korean patient with fulminant autoantibody-negative type 1 diabetes. Diabetes Care 27: 3023–3024
Taniyama M et al. (2004) A Filipino patient with fulminant type 1 diabetes. Diabetes Care 27: 842–843
Foulis AK et al. (1988) Massive synchronous B-cell necrosis causing type 1 (insulin-dependent) diabetes—a unique histopathological case report. Diabetologia 31: 46–50
Hanafusa T et al. (2005) Report of Japan diabetes society committee on fulminant type 1 diabetes mellitus: epidemiological and clinical analysis and proposal of diagnostic criteria [Japanese]. J Japan Diab Soc 48 (Suppl 1): A1–A13
Shimizu I et al. (2003) Association of fulminant type 1 diabetes with pregnancy. Diabetes Res Clin Pract 62: 33–38
Otsubo M et al. (2002) Nonimmune “fulminant” type 1 diabetes presenting with diabetic ketoacidosis during pregnancy. Obstet Gynecol 99: 877–879
Shimizu I et al. (2006) Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91: 471–476
Eisenbarth GS et al. (2003) Type 1 Diabetes Mellitus. In Williams Textbook of Endocrinology, edn 10, 1485–1504 (Eds Larsen PR et al.) Philadelphia: WB Saunders
Ikegami H and Ogihara T (1996) Genetics of insulin-dependent diabetes mellitus. Endocr J 43: 605–613
Imagawa A et al. (2005) Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48: 294–300
Sayama K et al. (2005) Pancreatic β and α cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment. Diabetologia 48: 1560–1564
Yamazaki M and Hayashi T (2002) Rapid-onset type 1 diabetes mellitus without pancreatic exocrine dysfunction. Ann Intern Med 137: 145–146
Itoh N et al. (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92: 2313–2322
Moriwaki M et al. (1999) Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type I diabetes mellitus. Diabetologia 42: 1332–1340
Tanaka S et al. (2000) A novel subtype of type 1 diabetes mellitus. N Engl J Med 342: 1835–1838
Uto Y et al. (2002) A case of fulminant type 1 diabetes mellitus detected after cardiac arrest due to diabetic ketoacidosis [Japanese]. J Japan Diab Soc 45: 689–693
Kobayashi T et al. (2005) A case of fulminant type 1 diabetes with ECG changes in the first trimester of pregnancy [Japanese]. J Jpn Soc Intensive Care Med 12: 25–30
Fukui K et al. (2002) A case of diabetes mellitus after acute pancreatitis with histological findings compatible to non-autoimmune fulminant type 1 diabetes [Japanese]. J Japan Diab Soc 45: 759–765
Takaike H et al. (2004) Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract 64: 27–32
Iwaoka T (2003) A case of fulminant type 1 diabetes with transiently positive anti-GAD antibodies. Endocr J 50: 225–231
Sekine N et al. (2001) Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 285: 1153–1154
Nagaoka T et al. (2001) Insulin-dependent diabetes mellitus following acute pancreatitis caused by herpes simplex virus: a case report [Japanese]. J Japan Diab Soc 44: 335–340
Nishida W et al. (2005) A case of fulminant type 1 diabetes associated with high titer of coxsackie B3 virus antibody [Japanese]. J Japan Diab Soc 48 (Suppl 1): A23–A27
Yamada K and Nonaka K (1996) Diabetic ketoacidosis in young obese Japanese men. Diabetes Care 19: 671
Sano H et al. (2005) Efficacy of intensive insulin therapy using ultra long acting insulin analog in fulminant type 1 diabetes: a comparison to continuous subcutaneous insulin infusion (CSII) therapy [abstract; Japanese]. J Japan Diab Soc 48 (Suppl 2): S249
Miura A et al. (2003) Efficacy of continuous subcutaneous insulin infusion (CSII) therapy for fulminant type 1 diabetes [Japanese]. J Japan Diab Soc 46 (Suppl 1): S221
Yamaguchi H et al. (2003) Prospective study of the capacity of insulin secretion of fulminant type 1 diabetic patients from the onset of diabetes [Japanese]. J Japan Diab Soc 46: 211–215
Wykes MN et al. (1993) Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection. J Virol 67: 4182–4189
Tanaka S et al. (2002) Association of HLA-DQ genotype in autoantibody-negative and rapid-onset type 1 diabetes. Diabetes Care 25: 2302–2307
Nakamura T et al. (2003) HLA-DR–DQ haplotype in rapid-onset type 1 diabetes in Japanese. Diabetes Care 26: 1640–1641
Shimada A and Maruyama T (2004) Encephalomyocarditis-virus-induced diabetes model resembles “fulminant” type 1 diabetes in humans. Diabetologia 47: 1854–1855
Ohta K et al. (2001) A case of fulminant type 1 diabetes mellitus during steroid therapy for hypersensitivity syndrome [Japanese]. J Japan Diab Soc 44: 907–912
Yamamoto S et al. (2003) A case of fulminant type 1 diabetes mellitus accompanied by hypersensitivity syndrome [Japanese]. J Japan Diab Soc 46: 949–954
Imagawa A et al. (2005) High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia 48: 290–293
Shimada A et al. (2002) T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes. Diabetes Care 25: 635–636
Kotani R et al. (2004) T lymphocyte response against pancreatic β cell antigens in fulminant Type 1 diabetes. Diabetologia 47: 1285–1291
Maruyama T et al. (1989) Insulin autoantibodies in mouse models of insulin-dependent diabetes. Diabetes Res 11: 61–65
Jun HS and Yoon JW (2001) The role of viruses in type I diabetes: two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia 44: 271–285
Taniguchi T et al. (2005) Autoantibodies against the exocrine pancreas in fulminant type 1 diabetes. Pancreas 30: 191–192
Acknowledgements
We are indebted to Drs N Itoh, J Miyagawa and Y Matsuzawa for discussions, also to the doctors of the Osaka IDDM study group and the Committee of the Japan Diabetes Society on the Research of Fulminant Type 1 Diabetes Mellitus for collaboration. This study was supported by the a grant-in-aid for scientific research from the Japan Society for the Promotion of Science, a grant-in-aid from the Japan Medical Association, and a grant from the Japan Diabetes Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hanafusa, T., Imagawa, A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Rev Endocrinol 3, 36–45 (2007). https://doi.org/10.1038/ncpendmet0351
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0351
This article is cited by
-
Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus
Diabetology & Metabolic Syndrome (2024)
-
Prevalence and prognosis of fulminant type 1 diabetes mellitus in The Middle East: a comparative analysis in a 5-year nationwide cohort
BMC Endocrine Disorders (2024)
-
Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade
Diabetologia (2022)
-
Modeling different types of diabetes using human pluripotent stem cells
Cellular and Molecular Life Sciences (2021)
-
Postmortem Diagnosis of Fulminant Type 1 Diabetes Mellitus: Case Report
SN Comprehensive Clinical Medicine (2021)